

# Long-acting Opioid Analgesics

## Goals:

- Restrict use of long-acting opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse.
- Restrict use of long-acting opioid analgesics for conditions of the back and/or spine due to evidence of increased risk vs. benefit.
- Promote the safe use of long-acting opioid analgesics by restricting use of high doses that have not demonstrated improved benefit and are associated with greater risk for accidental opioid overdose and death.

## Length of Authorization:

Initial: 90 days (except 12 months for end-of-life, sickle-cell disease, severe burn, or cancer-related pain)

Renewal: Up to 6 months

## Covered Alternatives:

- Current PMPDP preferred drug list per OAR 410-121-0030 at [www.orpdl.org](http://www.orpdl.org)
- Searchable site for Oregon FFS Drug Class listed at [www.orpdl.org/drugs/](http://www.orpdl.org/drugs/)

## Requires a PA:

- All long-acting opioids and opioid combination products.

## Note:

- Patients on palliative care with a terminal diagnosis or with cancer-related pain, or pain associated with sickle cell disease or severe burn injury are exempt from this PA.

**Table 1.** Daily Dose Threshold (90 Morphine Milligram Equivalents per Day) of Opioid Products.

Opioid	90 MME/day	Notes
Fentanyl (transdermal patch)	37.5 mcg/hr	Use only in opioid-tolerant patients who have been taking $\geq 60$ MME daily for a $\geq 1$ week. Deaths due to a fatal overdose of fentanyl have occurred when pets, children and adults were accidentally exposed to fentanyl transdermal patch. Strict adherence to the recommended handling and disposal instructions is of the utmost importance to prevent accidental exposure.)
Hydrocodone	90 mg	
Hydromorphone	22.5 mg	
Morphine	90 mg	
Oxycodone	60 mg	
Oxymorphone	30 mg	
Tapentadol	225 mg	
Tramadol	300 mg	300 mg/day is max dose and is not equivalent to 90 MME/day. Tramadol is not recommended for pediatric use as it is subject to different rates of metabolism placing certain populations at risk for overdose.
Methadone*	20 mg	<b>*DO NOT USE unless very familiar with the complex pharmacokinetic and pharmacodynamics properties of methadone.</b> Methadone exhibits a non-linear relationship due to its long half-life and accumulates with chronic dosing. Methadone also has complex interactions with several other drugs. The dose should not be increased more frequently than once every 7 days. Methadone is associated with an increased incidence of prolonged QTc interval, torsades de pointe and sudden cardiac death.

**Table 2.** Specific Long-acting Opioid Products Subject to Frequency Limits per FDA-approved Labeling.

Drug Product	Quantity Limit	Drug Product	Quantity Limit	Drug Product	Quantity Limit
BELBUCA	2 doses/day	HYSINGLA ER	2 doses/day	OXYCONTIN	2 doses/day
BUTRANS	1 patch/7 days	KADIAN	2 doses/day	TROXYCA ER	2 doses/day
EMBEDA	2 doses/day	MORPHABOND	2 doses/day	XARTEMIS XR	4 doses/day
EXALGO	1 dose/day	MS CONTIN	3 doses/day	XTAMPZA ER	2 doses/day
Fentanyl patch	1 dose/72 hr	NUCYNTA ER	2 doses/day	ZOHYDRO ER	2 doses/day
		OPANA ER	2 doses/day		

### Approval Criteria

1. What is the patient's diagnosis?	Record ICD10 code	
2. Is the request for a patient already established on any opioid treatment for >6 weeks (long-term, chronic treatment)?	<b>Yes:</b> Go to <b>Renewal Criteria</b>	<b>No:</b> Go to #3
3. Is the diagnosis funded by the OHP?  Note: Management of pain associated with <i>back or spine conditions with long-acting opioids</i> is not funded by the OHP*. Other conditions, such as fibromyalgia, TMJ, neuropathy, tension headache and pelvic pain syndrome are also not funded by the OHP.	<b>Yes:</b> Go to #4	<b>No:</b> Pass to RPh. Deny; not funded by the OHP.  Note: Management of opioid dependence is funded by the OHP.
4. Is the requested medication a preferred agent?	<b>Yes:</b> Go to #6	<b>No:</b> Go to #5
5. Will the prescriber change to a preferred product?  Note: Preferred opioids are reviewed and designated as preferred agents by the Oregon Pharmacy & Therapeutics Committee based on published medical evidence for safety and efficacy.	<b>Yes:</b> Inform prescriber of covered alternatives in class.	<b>No:</b> Go to #6
6. Is the patient being treated for pain associated with sickle cell disease, severe burn injury, cancer-related pain or under palliative care services with a life-threatening illness or severe advanced illness expected to progress toward dying?	<b>Yes:</b> Approve for up to 12 months	<b>No:</b> Go to #7
7. Is the prescription for pain associated with migraine or other type of headache?  Note: there is limited or insufficient evidence for opioid use for many pain conditions, including migraine or other types of headache.	<b>Yes:</b> Pass to RPh. Deny; medical appropriateness	<b>No:</b> Go to #8

8. Does the total daily opioid dose exceed 90 MME (see Table 1)?	<p><b>Yes:</b> Pass to RPh. Deny; medical appropriateness.</p> <p>Note: Management of opioid dependence is funded by the OHP.</p>	<b>No:</b> Go to #9
9. Is the prescriber enrolled in the Oregon Prescription Drug Monitoring Program ( <a href="http://www.orpdmp.com">www.orpdmp.com</a> ) and has the prescriber verified at least once in the past <u>month</u> that opioid prescribing is appropriate?	<p><b>Yes:</b> Go to #10</p>	<p><b>No:</b> Pass to RPh. Deny; medical appropriateness</p>
<p>10. Is the patient concurrently on other short- or long-acting opioids (patients may receive a maximum of one opioid product regardless of formulation)?</p> <p>Note: There is insufficient evidence for use of concurrent opioid products (e.g., long-acting opioid with short-acting opioid).</p>	<p><b>Yes:</b> Pass to RPh. Deny; medical appropriateness</p> <p>Note: Management of opioid dependence is funded by the OHP.</p>	<b>No:</b> Go to #11
<p>11. Is the patient currently taking a benzodiazepine or other central nervous system (CNS) depressant?</p> <p>Note: All opioids have a black box warning about the risks of profound sedation, respiratory depression, coma or death associated with concomitant use of opioids with benzodiazepines or other CNS depressants.</p>	<p><b>Yes:</b> Pass to RPh. Deny; medical appropriateness</p>	<b>No:</b> Go to #12
12. Does the prescription exceed quantity limits applied in Table 2 (if applicable)?	<p><b>Yes:</b> Pass to RPh. Deny; medical appropriateness</p>	<b>No:</b> Go to #13
<p>13. Can the prescriber provide documentation of sustained improvement of at least 30% in pain, function, or quality of life in the past 3 months compared to baseline?</p> <p>Note: Pain control, quality of life, and function can be quickly assessed using the 3-item PEG scale. **</p>	<p><b>Yes:</b> Go to #14</p> <p>Document tool used and score vs. baseline: _____</p>	<p><b>No:</b> Pass to RPh. Deny; medical appropriateness.</p> <p>Note: Management of opioid dependence is funded by the OHP.</p>
14. Has the patient had a urinary drug screen (UDS) within the past 3 months to verify absence of illicit drugs and non-prescribed opioids?	<p><b>Yes:</b> Approve for up to 90 days.</p>	<p><b>No:</b> Pass to RPh. Deny; medical appropriateness.</p> <p>Note: Management of opioid dependence is funded by the OHP.</p>

## Renewal Criteria

1. What is the patient's diagnosis?	Record ICD10 code	
2. Is the request for a patient already established on opioid treatment for >6 weeks (long-term treatment)?	<b>Yes:</b> Go to #3	<b>No:</b> Go to Approval Criteria
3. Does the request document a taper plan for the patient?	<b>Yes:</b> Document taper plan and approve for duration of taper or 3 months whichever is less.	<b>No:</b> Go to #4
4. Is there documentation indicating it is <b>unsafe</b> to initiate a taper at this time?	<b>Yes:</b> Go to #5  Document provider attestation and rationale	<b>No:</b> Pass to RPh. Deny; medical appropriateness
5. Is the prescriber enrolled in the Oregon Prescription Drug Monitoring Program ( <a href="http://www.orpdmp.com">www.orpdmp.com</a> ) and has the prescriber verified at least once in the past <u>1 month</u> that opioid prescribing is appropriate?	<b>Yes:</b> Go to #6	<b>No:</b> Pass to RPh. Deny. Medical appropriateness
6. Has the patient had a urinary drug screen (UDS) within the past year to verify absence of illicit drugs and non-prescribed opioids?	<b>Yes:</b> Go to #7	<b>No:</b> Pass to RPh. Deny. Medical appropriateness
7. Can the prescriber provide documentation of sustained improvement of at least 30% in pain, function, or quality of life in the past 3 months compared to baseline?  Note: Pain control, quality of life, and function can be quickly assessed using the 3-item PEG scale. **	<b>Yes:</b> Go to #9  Document tool used and score vs. baseline: _____	<b>No:</b> Go to #8
8. Has the patient been referred for alternative non-pharmacologic modalities of pain treatment (e.g., physical therapy, supervised exercise, spinal manipulation, yoga, or acupuncture)?	<b>Yes:</b> Go to #9	<b>No:</b> Pass to RPh. Deny. Medical appropriateness
9. Is the request for an increased cumulative dose compared to previously approved therapy or average dose in the past 6 weeks?	<b>Yes:</b> Go to #10	<b>No:</b> Go to #13
10. Does the prescription exceed quantity limits applied in Table 2 (if applicable)?	<b>Yes:</b> Pass to RPh. Deny; medical appropriateness	<b>No:</b> Go to #11

11. Does the total cumulative daily opioid dose exceed 90 MME (see Table 1)?	<b>Yes:</b> Pass to RPh. Deny; medical appropriateness	<b>No:</b> Go to #12
12. Is there documented rationale (e.g., new acute injury) to support the increase in dose?	<b>Yes:</b> Go to #13	<b>No:</b> Pass to RPh; deny; medical appropriateness
13. Does the patient have any of the following risk factors for overdose? <ol style="list-style-type: none"> <li>Concomitant CNS depressants (benzodiazepines, muscle relaxants, sedating antipsychotics, etc)</li> <li>Total daily opioid dose &gt; 90 MME or exceeding quantity limits in Table 2</li> <li>Recent urine drug screen indicating illicit or non-prescribed opioids</li> <li>Concurrent short- and long-acting opioid use</li> <li>Diagnosis of opioid use disorder</li> </ol>	<b>Yes:</b> Go to #14  Document number of risk factors	<b>No:</b> Go to #15
14. Has the member been prescribed or have access to naloxone?	<b>Yes:</b> Go to #15	<b>No:</b> Pass to RPh. Deny. Medical appropriateness
15. Does the patient have a pain contract on file with the prescriber?	<b>Yes:</b> Approved duration is based on the number of identified risk factors for overdose or length of treatment (whichever is less):  Risk factors: >=3: 2 month 1-2: 4 months 0: 6 months	<b>No:</b> Pass to RPh. Deny; medical appropriateness

\*See Guideline Note 60 within the Prioritized List of Health Services for conditions of coverage for pain associated with back or spine conditions: <http://www.oregon.gov/OHA/HPA/CSI-HERC/Pages/Prioritized-List.aspx>

\*\*The PEG is freely available to the public <http://www.agencymeddirectors.wa.gov/Files/AssessmentTools/1-PEG%203%20item%20pain%20scale.pdf>.

Citation of the original publication:

Krebs EE, Lorenz KA, Bair MJ, Damush TA, Wu J, Sutherland JM, Asch SM, Kroenke K. Development and initial validation of the PEG, a 3-item scale assessing pain intensity and interference. *Journal of General Internal Medicine*. 2009 Jun; 24:733-738.

### Clinical Notes:

#### How to Discontinue Opioids.

Adapted from the following guidelines on opioid prescribing:

- The Washington State Interagency Guideline on Prescribing Opioids for Pain; Agency Medical Directors' Group, June 2015.  
Available at <http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf>.

Selecting the optimal timing and approach to tapering depends on multiple factors. The decision to taper should be based on shared decision making between the patient and provider based on risks and benefits of therapy. Involving the patient in the decision to taper helps establish trust with the patient, ensures patient-focused tapering, incorporates the patient's values into the taper plan, provides education on the risks of opioid use, and establishes realistic goals and expectations.

Avoid insisting on opioid tapering or discontinuation when opioid use may be warranted. The rate of opioid taper should be based primarily on safety considerations, and special attention is needed for patients on high dose opioids or with significant long-term use, as too rapid a taper may precipitate withdrawal symptoms or drug-seeking behavior. In addition, behavioral issues or physical withdrawal symptoms can be a major obstacle during an opioid taper. Patients who feel overwhelmed or desperate may try to convince the provider to abandon the taper. Although there are no methods for preventing behavioral issues during taper, strategies implemented at the beginning of chronic opioid therapy such as setting clear expectations, allowing for pauses during the taper, and development of an exit strategy are most likely to prevent later behavioral problems if a taper becomes necessary.

1. Consider sequential tapers for patients who are on chronic benzodiazepines and opioids. Coordinate care with other prescribers (e.g. psychiatrist) as necessary. In general, taper off opioids first, then the benzodiazepines.
2. Do not use ultra-rapid detoxification or antagonist-induced withdrawal under heavy sedation or anesthesia (e.g. naloxone or naltrexone with propofol, methohexitol, ketamine or midazolam).
3. Establish an individualized rate of taper based on safety considerations and patient history. Common tapers have a dose reduction of 5% to 20% per month:
  - a. Assess for substance use disorder and transition to appropriate medication assisted treatment if there is diversion or non-medical use,
  - b. Rapid taper (over a 2 to 3 week period) if the patient has had a severe adverse outcome such as overdose or substance use disorder, or
  - c. Slow taper for patients with no acute safety concerns. May consider starting with a taper of ≤10% of the original dose per month and assess the patient's functional and pain status at each visit.
4. Adjust the rate, intensity, and duration of the taper according to the patient's response (e.g. emergence of opioid withdrawal symptoms (see Table below)).
5. Watch for signs of unmasked mental health disorders (e.g. depression, PTSD, panic disorder) during taper, especially in patients on prolonged or high dose opioids. Consult with specialists to facilitate a safe and effective taper. Use validated tools to assess conditions.
6. Consider the following factors when making a decision to continue, pause or discontinue the taper plan:
  - a. Assess the patient behaviors that may be suggestive of a substance use disorder
  - b. Address increased pain with use of non-opioid pharmacological and non-pharmacological options.
  - c. Evaluate patient for mental health disorders.
  - d. If the dose was tapered due to safety risk, once the dose has been lowered to an acceptable level of risk with no addiction behavior(s) present, consider maintaining at the established lower dose if there is a clinically meaningful improvement in function, reduced pain and no serious adverse outcomes.
7. Do not reverse the taper; it must be unidirectional. The rate may be slowed or paused while monitoring for and managing withdrawal symptoms.
8. Increase the taper rate when opioid doses reach a low level (e.g. <15 mg/day MED), since formulations of opioids may not be available to allow smaller decreases.
9. Use non-benzodiazepine adjunctive agents to treat opioid abstinence syndrome (withdrawal) if needed. Unlike benzodiazepine withdrawal, opioid withdrawal symptoms are rarely medically serious, although they may be extremely unpleasant. Symptoms of mild opioid withdrawal may persist for 6 months after opioids have been discontinued (see Table below).
10. Refer to a crisis intervention system if a patient expresses serious suicidal ideation with plan or intent, or transfer to an emergency room where the patient can be closely monitored.
11. Do not start or resume opioids or benzodiazepines once they have been discontinued, as they may trigger drug cravings and a return to use. Counsel the patient on the increased risk of overdose with abrupt return to a previously prescribed higher dose. Provide opioid overdose education and consider offering naloxone.
12. Consider inpatient withdrawal management if the taper is poorly tolerated.

### Symptoms and Treatment of Opioid Withdrawal.

Adapted from the Washington State Interagency Guideline on Prescribing Opioids for Pain; Agency Medical Directors' Group, June 2015. Available at <http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf>

Restlessness, sweating or tremors	Clonidine 0.1-0.2 mg orally every 6 hours or transdermal patch 0.1-0.2 mg weekly (If using the patch, oral medication may be needed for the first 72 hours) during taper. Monitor for significant hypotension and anticholinergic side effects.
Nausea	Anti-emetics such as ondansetron or prochlorperazine
Vomiting	Loperamide or anti-spasmodics such as dicyclomine
Muscle pain, neuropathic pain or myoclonus	NSAIDs, gabapentin or muscle relaxants such as cyclobenzaprine, tizanidine or methocarbamol

Insomnia	Sedating antidepressants (e.g. nortriptyline 25 mg at bedtime or mirtazapine 15 mg at bedtime or trazodone 50 mg at bedtime). Do not use benzodiazepines or sedative-hypnotics.
----------	---

P&T Review: 4/21(AG); 2/20 (SS), 9/19 (DM), 3/17; 11/16; 05/16

Implementation: 5/1/21; 3/1/20; 10/1/19